| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IDXX | Common Stock | Options Exercise | $1.25M | +24K | +46.57% | $52.00* | 75.5K | Nov 7, 2022 | Direct | F1 |
| transaction | IDXX | Common Stock | Sale | -$341K | -900 | -1.19% | $378.60 | 74.6K | Nov 7, 2022 | Direct | F2 |
| transaction | IDXX | Common Stock | Sale | -$759K | -2K | -2.68% | $379.50 | 72.6K | Nov 7, 2022 | Direct | F3 |
| transaction | IDXX | Common Stock | Sale | -$190K | -500 | -0.69% | $380.85 | 72.1K | Nov 7, 2022 | Direct | F4 |
| transaction | IDXX | Common Stock | Sale | -$1.42M | -3.7K | -5.13% | $382.81 | 68.4K | Nov 7, 2022 | Direct | F5 |
| transaction | IDXX | Common Stock | Sale | -$1.04M | -2.72K | -3.97% | $383.29 | 65.7K | Nov 7, 2022 | Direct | F6 |
| transaction | IDXX | Common Stock | Sale | -$1.16M | -3.02K | -4.59% | $384.47 | 62.7K | Nov 7, 2022 | Direct | F7 |
| transaction | IDXX | Common Stock | Sale | -$151K | -392 | -0.63% | $385.01 | 62.3K | Nov 7, 2022 | Direct | F8 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IDXX | Non-Qualified Stock Option (right-to-buy) | Options Exercise | -24K | -100% | 0 | Nov 7, 2022 | Common Stock | 24K | $52.00 | Direct | F9, F10 |
| Id | Content |
|---|---|
| F1 | Includes 17 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2022 |
| F2 | Represents the weighted average price of the shares sold ranging from a low of $377.99 to a high of $378.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F3 | Represents the weighted average price of the shares sold ranging from a low of $379.10 to a high of $380.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F4 | Represents the weighted average price of the shares sold ranging from a low of $380.68 to a high of $381.04 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F5 | Represents the weighted average price of the shares sold ranging from a low of $381.94 to a high of $382.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F6 | Represents the weighted average price of the shares sold ranging from a low of $382.95 to a high of $383.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F7 | Represents the weighted average price of the shares sold ranging from a low of $383.97 to a high of $384.935 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F8 | Represents the weighted average price of the shares sold ranging from a low of $384.98 to a high of $385.16 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| F9 | Grant of option to buy 24,501 shares of Issuer common stock that became exercisable in five annual installments beginning December 5, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
| F10 | Not applicable. |